2024年8月02日

Mayer Brown advises SERB Pharmaceuticals and its majority shareholder Charterhouse Capital Partners on the structuring of the acquisition of RSDL® (Reactive Skin Decontamination Lotion)

Share

Mayer Brown advises SERB Pharmaceuticals and its majority shareholder Charterhouse Capital Partners on the structuring of the acquisition of RSDL® (Reactive Skin Decontamination Lotion) from Emergent BioSolutions Inc. (NYSE: EBS). RSDL® is a medical device produced as a kit that removes or neutralizes chemical warfare agents from the skin.

連絡先

関連サービスと産業

最新のInsightsをお届けします

クライアントの皆様の様々なご要望にお応えするための、当事務所の多分野にまたがる統合的なアプローチをご紹介します。
購読する